竟天（6917）16日公告，用于缓解头颈部带状疱疹后神经痛的喷雾新药APC101，于今年4月获TFDA核准启动二期临床试验后，已成功在三军总医院收治首位病患。

竟天(6917)用于缓解头颈部带状疱疹后神经痛的喷雾新药APC101，于今年4月获TFDA核准启动二期临床试验后，已成功在三军总医院收治首位病患。 竟天头颈部带状疱疹后神经痛目前并无有效的已上市药物，公司预计在完成二期临床，取得相关试验数据，将向美国FDA争取申请快速审查认定(Fast Track Designation)或孤儿药资格认定(Orphan Drug Designation)，推动新药 ...

Anyone that’s attended a wedding, a cocktail party, heck, even endured an extra long day at work can attest: Standing tall in ...

Most of us think shingles is an old person’s disease. But the reality is, it can strike at any time, triggered by ...

Discover why Vertex stock is undervalued with the potential of VX-548 as a groundbreaking pain treatment drug in the ...

Paul Christian, from Southport, suffered life-changing injuries following a freak accident at work which left him with a ...

A grandad's life was changed forever after a “horrendous” workplace incident. Paul Christian, from Southport, had to retire ...

If you are planning to have oral surgery or another surgery requiring a local anesthetic, you might be concerned about the ...

GTX-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aSAH patients to address significant unmet medical needs. The unique ...

GTX-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aSAH patients to address significant unmet medical needs. The unique ...